down arrow

Aclaris Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US00461U1051
  • NASDAQ: ACRS
USD
5.26
-0.46 (-8.04%)

Sep 23

NAS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Kiniksa Pharmaceuticals Ltd.
Tarsus Pharmaceuticals, Inc.
Repare Therapeutics, Inc.
Phathom Pharmaceuticals, Inc.
Evolus, Inc.
Aclaris Therapeutics, Inc.
Harrow, Inc.
GH Research Plc
Savara, Inc.
Olema Pharmaceuticals, Inc.
Rapt Therapeutics, Inc.

Why is Aclaris Therapeutics, Inc. ?

1
Poor long term growth as Operating profit has grown by an annual rate -13.75% of over the last 5 years
2
The company has declared Negative results for the last 6 consecutive quarters
  • NET SALES(Q) At USD 1.63 MM has Fallen at -22.12%
  • PRE-TAX PROFIT(Q) Lowest at USD -21.2 MM
  • CASH AND EQV(HY) Lowest at USD 196.97 MM
3
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 196.37%, its profits have fallen by -55.9%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Aclaris Therapeutics, Inc. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Aclaris Therapeutics, Inc.
187.43%
4.41
99.73%
S&P 500
15.76%
1.22
13.15%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
3.86%
EBIT Growth (5y)
-13.75%
EBIT to Interest (avg)
-71.59
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.73
Sales to Capital Employed (avg)
0.16
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
86.14%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.12
EV to EBIT
-4.53
EV to EBITDA
-4.57
EV to Capital Employed
25.95
EV to Sales
42.72
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-573.47%
ROE (Latest)
-60.56%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bullish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company
NET PROFIT(HY)

Higher at USD -41.03 MM

RAW MATERIAL COST(Y)

Fallen by -291.78% (YoY

-22What is not working for the Company
NET SALES(Q)

At USD 1.63 MM has Fallen at -22.12%

PRE-TAX PROFIT(Q)

Lowest at USD -21.2 MM

CASH AND EQV(HY)

Lowest at USD 196.97 MM

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.57 times

OPERATING PROFIT(Q)

Lowest at USD -23.83 MM

NET PROFIT(Q)

Lowest at USD -21.2 MM

Here's what is working for Aclaris Therapeutics, Inc.

Raw Material Cost
Fallen by -291.78% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Aclaris Therapeutics, Inc.

Net Sales
At USD 1.63 MM has Fallen at -22.12%
over average net sales of the previous four periods of USD 2.09 MM
MOJO Watch
Near term sales trend is extremely negative

Net Sales (USD MM)

Pre-Tax Profit
Lowest at USD -21.2 MM and Fallen
In each period in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Operating Profit
Lowest at USD -23.83 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is negative

Operating Profit (USD MM)

Pre-Tax Profit
At USD -21.2 MM has Fallen at -25.36%
over average net sales of the previous four periods of USD -16.92 MM
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit
Lowest at USD -21.2 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is negative

Net Profit (USD MM)

Net Profit
At USD -21.2 MM has Fallen at -25.36%
over average net sales of the previous four periods of USD -16.92 MM
MOJO Watch
Near term Net Profit trend is negative

Net Profit (USD MM)

Cash and Eqv
Lowest at USD 196.97 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debtors Turnover Ratio
Lowest at 2.57 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Footer loading